Navigation Links
George M. Whitesides receives inaugural Dreyfus prize in the chemical sciences
Date:5/6/2009

rea of materials chemistry, including challenges in energy, water, conservation, sustainabilitycommodity infrastructure is up to us, as chemists, to work through."

Among Whitesides's many innovations are the synthesis and molecular organization of new classes of materials, pioneering self-assembled monolayers and microfluidic systems to enable the development of new drugs and extend soft materials into the world of three-dimensional microelectronics, and into consumer devices such as solar cells. Within this work he developed soft lithography, a set of methods for printing and molding organic-based substances to make complex patterns at the micron and nanometer level.

Whitesides combined these approaches for creating materials with the concept of polyvalency and developed a new paradigm for drug design. This has resulted in affordable medical diagnostics expected to have a major impact on health in the third world as well as new drugs that manage cholesterol, improve dialysis, and combat multiple drug-resistant pathogens.

Henry C. Walter, President of the Dreyfus Foundation, said, "I believe the Dreyfus brothersmaterials chemists, inventors, and businessmenwould be very proud to honor George Whitesides, a chemist who has generated so much value to society based on his innovative chemistry research. It reflects the Dreyfus Foundation charter admirably."

Marye Anne Fox, Chancellor of the University of California, San Diego, and Chair of the Dreyfus Scientific Affairs Committee, noted, "George has revolutionized materials chemistry. He has developed a unique interdisciplinary approach to materials systems that is of widespread influence in chemistry research."

George Whitesides has received many awards. Among those from the American Chemical Society are the Award in Pure Chemistry, the Arthur C. Cope Award, and the Society's highest award, the Priestley Medal. From other institutions his awards include the Materials Resea
'/>"/>

Contact: Mark Cardillo
mcardillo@dreyfus.org
212-753-1760
The Camille and Henry Dreyfus Foundation, Inc.
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. DHS Begins Collecting 10 Fingerprints From International Visitors at George Bush Houston Intercontinental Airport
2. Researchers offer new theory for dogfish and skate population outburst on Georges Bank
3. Healthy parents provide clues to survival of young haddock on Georges Bank
4. Georgetown Universitys Howard J. Federoff, M.D., Ph.D. receives Bernard Sanberg Memorial Award
5. Rutgers Genetics receives $7.8 million for autism research
6. Herr receives Heinz Award for Technology, the Economy and Employment
7. UCI receives $5M from Edwards Lifesciences
8. Yu receives research funding from the Wallace H. Coulter Foundation
9. UGA Odum School of Ecology professor receives grant to study West Nile Virus in NYC
10. UC Riverside biologist receives prestigious MacArthur Fellowship
11. UC Irvine receives $2.18M to explore nano advancements in DNA sequencing

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)... , Sewer overflows are a nasty business, posing d...Carolina State University is launching a new proje...tion Agency (EPA) that targets the fat and grease ...r, and will give urban planners new tools to furth...are overflows from "sanitary" sewer systems, as op...
(Date:11/22/2009)... , CINCINNATI -- Children exposed prenatally to t...articularly high risk for ADHD, according to resea... Center. , The study estimates that up to 35 per... 8 and 15 could be reduced by eliminating both of ...e into up to 800,000 children , "Tobacco and le...
(Date:11/22/2009)... , A commonly inherited gene deletion can increas... bone marrow transplantation, an international tea...e online issue of Nature Genetics . When the gene...me but present in the recipient,s, transplants hav...ffect known as graft-versus-host disease, in which...
Breaking Biology News(10 mins):Lose the fat: Targeting grease to curtail sewer overflows 2Exposure to lead, tobacco smoke raises risk of ADHD 2Gene mismatch influences success of bone marrow transplants 2Gene mismatch influences success of bone marrow transplants 3Gene mismatch influences success of bone marrow transplants 4BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis 4678 1BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis 4678 2Reverse Ages Staying Young Naturally 50696 1ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB 402 4677 1ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB 402 4677 2ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB 402 4677 3ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB 402 4677 4ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB 402 4677 5
...ctors from different hospitals can collaborate on ...rating room. What if doctors in remote locations c...cialists in hospitals around the world? , This en...search by a multi-university partnership that is t...dvanced networking consortium Internet2. , Roche...
...g is causing the worldwide declines of amphibians ...cording to biologists. The findings, which contrad...is killing the frogs and toads and aid in their co... sixth mass extinction event," said Peter Hudson, ...d co-author of the research study. "And amphibians...
...matodes are extreme parasites. These microscopic, ...ral and field crops in sub-tropical regions, resul...d gardeners. , Until recently, fumigation of the ...rimary method for controlling root-knot nematodes ... is an odorless, colorless gas that has been widel...
Other Biology News:The next step in health care: Telemedicine 2Global warming link to amphibian declines in doubt 2Global warming link to amphibian declines in doubt 3Parasite-resistant peppers green alternatives to chemical pesticides 2
(Date:11/19/2009).../ - Aegera Therapeutics Inc. announced today the d...B study of AEG35156, a targeted antisense therapeu... indications. ,, The study, entitled "An Open-L...bitor of Apoptosis (XIAP) Antisense AEG35156 Given...ubicin in AML Following Failure of a Single Standa...
(Date:11/19/2009)...ne Synthesis Companies Form International Gene Syn...ces in Risk Reduction ,Five Member Companies Rep...city , (PRWEB) November 1...synthesis companies today announced agreement that...omote biosecurity in the gene synthesis industry. ...
(Date:11/19/2009)...mber 19 AFFiRiS AG will focus its,...te at an unexpectedly early,stage of development: ...o,Phase II clinical trial early in 2010. This deci...tion of two Phase I trials with the candidates,AD0... the first interim,analysis of the secondary endpo...
(Date:11/18/2009)... Standards and Technology (NIST) has demonstrated ...ing and measuring elusive hazards such as conceale...d or pesticides distributed in soil by wind and ra...nventional techniques for detecting traces of thes...having distinct electrically positive and negative...
Breaking Biology Technology:Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3Prototype NIST method detects and measures elusive hazards 2
...ent, BASEL, Switzerland and TUCSON, Ariz., Jan. 2...d-leading healthcare,provider of pharmaceuticals a...ana") (Nasdaq: VMSI ) today announced that they h...e terms of the agreement, Roche will,increase the ...mon shares,to $89.50 per share in cash (or an aggr...
...x,Orthobiology B.V. announced today the closure of...y BioGeneration Ventures., Progentix Orthobiology...e suite of osteoinductive material products for cl...rogentix bone graft material is based on,surface s...the ability to,attract growth factors and stems ce...
...s,announced that it will continue to provide Avast...thalmologists who request it for their patients.,T..., Genentech,s, decision,( http://www.lucentis.com/...Avastin directly to compounding pharmacies as of J...tinal specialists and,ophthalmologists to treat ag...
Other Biology Technology:Roche to Acquire Ventana for $89.50 per share 2Roche to Acquire Ventana for $89.50 per share 3Roche to Acquire Ventana for $89.50 per share 4Roche to Acquire Ventana for $89.50 per share 5Roche to Acquire Ventana for $89.50 per share 6Progentix Orthobiology B.V. Closes Series A Financing Round 2Wedgewood Pharmacy Will Continue to Provide Avastin(R) to Ophthalmologists and Retinal Specialists 2Wedgewood Pharmacy Will Continue to Provide Avastin(R) to Ophthalmologists and Retinal Specialists 3
Eosinophil Chip-IHC from 3H Biomedical AB
B Cell Chip-IHC from 3H Biomedical AB
Basophil Chip-IHC from 3H Biomedical AB
UCB CD4 T Cell Chip-IHC from 3H Biomedical AB
Biology Products: